IL276386B2 - Heterocyclic nitrogenated amide compounds, preparations containing them and their uses - Google Patents
Heterocyclic nitrogenated amide compounds, preparations containing them and their usesInfo
- Publication number
- IL276386B2 IL276386B2 IL276386A IL27638620A IL276386B2 IL 276386 B2 IL276386 B2 IL 276386B2 IL 276386 A IL276386 A IL 276386A IL 27638620 A IL27638620 A IL 27638620A IL 276386 B2 IL276386 B2 IL 276386B2
- Authority
- IL
- Israel
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- compound
- compound represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 | ||
| PCT/JP2019/003052 WO2019151274A1 (ja) | 2018-02-01 | 2019-01-30 | 含窒素複素環アミド化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL276386A IL276386A (en) | 2020-09-30 |
| IL276386B2 true IL276386B2 (en) | 2023-06-01 |
Family
ID=67479787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276386A IL276386B2 (en) | 2018-02-01 | 2020-07-29 | Heterocyclic nitrogenated amide compounds, preparations containing them and their uses |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10800784B2 (enExample) |
| EP (1) | EP3747888A4 (enExample) |
| JP (3) | JP7241556B2 (enExample) |
| KR (1) | KR102725118B1 (enExample) |
| CN (1) | CN111655692B (enExample) |
| AR (1) | AR114237A1 (enExample) |
| AU (1) | AU2019214048B2 (enExample) |
| BR (1) | BR112020014177A2 (enExample) |
| CA (1) | CA3090219A1 (enExample) |
| CL (1) | CL2020002003A1 (enExample) |
| CO (1) | CO2020009420A2 (enExample) |
| IL (1) | IL276386B2 (enExample) |
| MX (1) | MX2020008126A (enExample) |
| MY (1) | MY205011A (enExample) |
| PE (1) | PE20211273A1 (enExample) |
| PH (1) | PH12020500613A1 (enExample) |
| SA (1) | SA520412473B1 (enExample) |
| SG (1) | SG11202006916SA (enExample) |
| TW (1) | TWI803570B (enExample) |
| WO (1) | WO2019151274A1 (enExample) |
| ZA (1) | ZA202004548B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220362215A1 (en) | 2018-09-11 | 2022-11-17 | Japan Tobacco Inc. | Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| CN119874775A (zh) | 2020-02-07 | 2025-04-25 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| MX2022010950A (es) * | 2020-03-04 | 2022-10-07 | Japan Tobacco Inc | Compuesto triciclico fusionado y uso farmaceutico del mismo. |
| EP4211139A4 (en) * | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3213837A1 (en) * | 2021-03-23 | 2022-09-29 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Heterocycle substituted ketone derivative, and composition and medicinal use thereof |
| EP4438040A4 (en) | 2021-09-01 | 2025-08-20 | Japan Tobacco Inc | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND ITS PHARMACEUTICAL USE |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) * | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| RU2009148865A (ru) * | 2007-06-01 | 2011-07-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| US9409924B2 (en) | 2011-06-27 | 2016-08-09 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| US9944600B2 (en) | 2012-06-12 | 2018-04-17 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for GPR119 agonist |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| PL2975028T3 (pl) * | 2013-03-15 | 2018-10-31 | Japan Tobacco, Inc. | Związek pirazoloamidowy i jego zastosowania medyczne |
| JP2015028009A (ja) * | 2013-07-01 | 2015-02-12 | 日本たばこ産業株式会社 | ピラゾール−アルコール化合物およびその医薬用途 |
| JP2015028010A (ja) * | 2013-07-01 | 2015-02-12 | 日本たばこ産業株式会社 | フルオレン−アミド化合物およびその医薬用途 |
| GB201316823D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| CA2933927C (en) | 2013-12-17 | 2021-11-16 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| US10526325B2 (en) | 2015-07-31 | 2020-01-07 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| CN108779093B (zh) | 2016-03-29 | 2021-03-09 | 默克专利股份公司 | 作为丙酮酸脱氢酶激酶的抑制剂的n1-(3,3,3-三氟-2-羟基-2-甲基丙酰基)-哌啶衍生物 |
| US10428024B2 (en) * | 2016-04-28 | 2019-10-01 | Merck Patent Gmbh | Piperidinyl derivatives |
| KR20190036549A (ko) * | 2016-07-29 | 2019-04-04 | 니뽄 다바코 산교 가부시키가이샤 | 피라졸-아미드 화합물의 제조 방법 |
| EP3496716B1 (en) | 2016-08-15 | 2021-11-03 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| PT3532064T (pt) | 2016-10-28 | 2020-09-03 | H Lundbeck As | Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| MX2022010950A (es) * | 2020-03-04 | 2022-10-07 | Japan Tobacco Inc | Compuesto triciclico fusionado y uso farmaceutico del mismo. |
| EP4438040A4 (en) * | 2021-09-01 | 2025-08-20 | Japan Tobacco Inc | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND ITS PHARMACEUTICAL USE |
-
2019
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/ja active Active
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/zh active Active
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 MY MYPI2020003575A patent/MY205011A/en unknown
- 2019-01-30 AR ARP190100202A patent/AR114237A1/es unknown
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/pt unknown
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/ja not_active Ceased
- 2019-01-30 KR KR1020207024426A patent/KR102725118B1/ko active Active
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/es unknown
- 2019-01-30 TW TW108103504A patent/TWI803570B/zh active
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/es unknown
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/ar unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/es unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/es unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/ja not_active Ceased
- 2023-09-05 US US18/460,821 patent/US20240300952A1/en not_active Abandoned
-
2024
- 2024-06-12 JP JP2024094812A patent/JP2024116307A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276386B2 (en) | Heterocyclic nitrogenated amide compounds, preparations containing them and their uses | |
| JP6208603B2 (ja) | ピラゾール−アミド化合物およびその医薬用途 | |
| JP2009527550A (ja) | 癌を処置する方法 | |
| JP2015028010A (ja) | フルオレン−アミド化合物およびその医薬用途 | |
| JP2009528996A (ja) | ヌクレオシドホスホリラーゼ及びヌクレオシダーゼの阻害剤を用いて疾患を処置する方法 | |
| EP4116301B1 (en) | Fused tricyclic compound and medicinal use thereof | |
| Nguyen et al. | Triheptanoin alleviates ventricular hypertrophy and improves myocardial glucose oxidation in rats with pressure overload | |
| WO2015002119A1 (ja) | ピラゾール－アルコール化合物およびその医薬用途 | |
| US20140296316A1 (en) | Hydrate and crystal of fluorene compounds | |
| RU2833338C1 (ru) | Конденсированное трициклическое соединение и его применение в медицине | |
| Ma et al. | Emerging therapy strategies for energy metabolism in acute myocardial infarction | |
| US20210204539A1 (en) | Method for Suppressing Freezing Damage and Composition for Preventing Freezing Damage | |
| WO2006087718A1 (en) | Extension of lifespan with drugs | |
| NO863386L (no) | Analogifremgangsmaate for fremstilling av komplekser av visse cardiotoniske fosfodiesterase-inhibitorer og vannopploeselige vitaminer. | |
| NZ712292A (en) | Pyrazole-amide compound and medicinal uses therefor | |
| NZ712292B2 (en) | Pyrazole-amide compound and medicinal uses therefor |